Thrasos Therapeutics, a Montréal-based biotech company, has just completed a US$21-million financing round allowing it to complete Phase-2 clinical trials of its THR-184 treatment for acute kidney injury (AKI). The funding will also enable Thrasos to pursue its work on chronic kidney disease.
“These funds will allow us to continue our critical work directed at the prevention of AKI in patients undergoing major surgery, in addition to extending our core technology into chronic kidney disease (CKD),” explained Richard Andrews, President and CEO of Thrasos Therapeutics.
THR-184, a promising treatment
Over one million people suffer from acute kidney injury every year in North America. The disease usually affects patients who undergo
THR-184, a highly promising treatment for AKI, is currently being tested by Thrasos in a major clinical trial focusing on patients who are scheduled for cardiac surgery and are at risk of developing AKI.
"There are no existing preventative therapies that can reduce the impact on patients, hospitals and taxpayers,” said Jens Eckstein, Ph.D., President of SR One and Chairman of the Board of Thrasos. “THR-184 has the potential to make a significant impact in this area."
Visit the Thrasos Therapeutics website.